Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE E GARBO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1740276484
CMS profile
350947
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$259.57

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.57 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE E GARBO

NPI 1740276484 · CMS profile ID 350947

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740276484?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740276484?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740276484?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1740276484?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $259.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $84.4208/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644451 CMS
Genentech USA, Inc. $81.2206/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681303925 CMS
Medical Device Business Services, Inc. $93.9303/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655886821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $259.57 3
PY2020 $15.32 1
PY2021 $62.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,555.31 21
PY2024 Principal investigator $121,551.17 52
PY2023 Principal investigator $130,237.17 26
PY2022 Principal investigator $53,938.23 20
PY2021 Principal investigator $175,090.52 37
PY2020 Principal investigator $226,774.25 81
PY2019 Principal investigator $398,858.14 215

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $718.50 12/31/2023 Non-covered Recipient Entity
NY ONCOLOGY HEMATOLOGY
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies No dispute reported 06/30/2026 998413439
Principal investigator 1 Merck Sharp & Dohme LLC $0.01 12/31/2023 Non-covered Recipient Entity
New York Oncology Hematology P.C
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 1042495753
Principal investigator 1 Merck Sharp & Dohme LLC $0.03 12/31/2023 Non-covered Recipient Entity
New York Oncology Hematology P.C
A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced,Metastatic Siewert Type 1 Adenocarcinoma of the Esophagogastric JunctionKEYNOTE-180 No dispute reported 06/30/2026 1042495797
Principal investigator 1 BioNTech SE $4,138.00 11/28/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060316949
Principal investigator 1 BioNTech SE $2,951.00 11/07/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060316945
Principal investigator 1 BioNTech SE $6,207.00 10/17/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060316947
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,190.00 10/15/2023 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027451713
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $476.00 10/15/2023 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027451727
Principal investigator 1 BioNTech SE $882.00 10/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060316943
Principal investigator 1 BioNTech SE $968.00 08/23/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060313485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.09 08/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1039746575
Principal investigator 1 BioNTech SE $968.00 08/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060318019
Principal investigator 1 Genentech, Inc. $6,916.40 07/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.04 05/16/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1039709255
Principal investigator 1 BioNTech SE $2,951.00 05/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060317969
Principal investigator 1 BioNTech SE $2,374.00 04/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Pre-commercial No dispute reported 06/30/2026 1060317971
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,484.00 04/24/2023 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 1000206687
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,483.00 04/24/2023 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 1000206717
Principal investigator 1 Merck Sharp & Dohme LLC $76,410.00 03/13/2023 Non-covered Recipient Entity
New York Oncology Hematology P.C
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 1042495547
Principal investigator 1 Genentech, Inc. $6,383.00 03/01/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040572887
Principal investigator 1 Genentech, Inc. $831.48 03/01/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE No dispute reported 06/30/2026 1040576869
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $992.00 02/27/2023 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 1000206701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $253.02 02/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1039705465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,344.60 01/15/2023 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY, PC
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991141101
Principal investigator 1 Celgene Corporation $3,332.00 01/15/2023 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026490515
Principal investigator 1 Celgene Corporation $1,428.00 01/15/2023 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026490531